Sign up to save your podcasts
Or
Share Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
A combination product is now available of niraparib + abiraterone for use in mCRPC.
Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
View all episodes
By John Bossaer
4.9
179179 ratings
A combination product is now available of niraparib + abiraterone for use in mCRPC.
Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
More shows like OncoPharm
View all
JAMA Editors' Summary
127 Listeners
NEJM This Week
317 Listeners
JAMA Clinical Reviews
479 Listeners
The Curbsiders Internal Medicine Podcast
3,318 Listeners
Up First from NPR
56,072 Listeners
Core IM | Internal Medicine Podcast
1,084 Listeners
The ONS Podcast
196 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
695 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
318 Listeners
The Curious Clinicians
364 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
165 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
37 Listeners